sodium lactate ringer's injection 250ml
Indications
Sodium Lactate Ringer's Injection is indicated as a source of water and electrolytes or as an alkalinizing agent.
Dosage and Administration
Dosage:
The recommended dosage is:
1.For adults: 500 ml to 3 L/24h
2.For infants, toddlers and children: 20 ml to 100 ml/kg/24 h
Usage:
Intravenous Injection
Contraindications:
1.A known hypersensitivity to sodium lactate.
2 Extracellular hyperhydration or hypervolaemia
3.Severe renal insufficiency (with oliguria/anuria)
4.Uncompensated cardiac failure
5.Hyperkalaemia
6.Hypercalcaemia
7.Metabolic alkalosis
8.Ascitic cirrhosis
9.Severe metabolic acidosis
10.Conditions associated with increased lactate levels (hyperlactataemia) including lactic acidosis, or impaired lactate utilization, such as severe hepatic insufficiency.
11.Concomitant digitalis therapy
Precautions&warning:
1.Hypersensitivity reactions
2.Incompatibilities:In patients older than 28 days (including adults), ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Sodium Lactate Ringer's Injection, through the same infusion line. If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid.
3.Electrolyte balance:Hypernatraemia; Hyperchloraemia; Use in patients with potassium deficiency; Use in patients at risk for hyperkalaemia; Use in patients at risk for hypercalcaemia
4.Fluid balance/renal function
5.Acid-base balance
Adverse reaction:
1.Immune System Disorders: Hypersensitivity/Infusion reactions including Anaphylactic/Anaphylactoid reaction, possibly manifested by one or more of the following symptoms: Angioedema, Chest pain, Chest discomfort, Decreased heart rate, Tachycardia, Blood pressure decreased, Respiratory distress, Bronchospasm, Dyspnea, Cough, Urticaria, Rash, Pruritus, Erythema, Flushing, Throat irritation, Paresthesias, Hypoesthesia oral, Dysgeusia, Nausea, Anxiety, Pyrexia, Headache
2.Metabolism and Nutrition Disorders: Hyperkalaemia; Hospital acquired hyponatraemia.
3.Nervous system disorders: Acute hyponatraemic encephalopathy
Drug interactions:
1.Drugs leading to an increased vasopressin effect:
Drugs stimulating vasopressin release include: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics; Drugs potentiating vasopressin action include: Chlorpropamide, NSAIDs, cyclophosphamide; Vasopressin analogues include: Desmopressin, oxytocin, terlipressin; Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
2.Interaction related to the presence of sodium:corticosteroids.
3.Interaction related to the presence of potassium: Potassium-sparing diuretics (amiloride, spironolactone, triamterene, alone or in association); Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists; Tacrolimus, cyclosporine.
Storage instructions:
Do not store above 30° C